Comparing GLP-1, GIP, and Glucagon Receptor Agonism: Tirzepatide and Retatrutide Side by Side

Our history of GLP-1 receptor agonist research traced how the field moved from single-target compounds toward multi-receptor agonists. This article goes one level deeper into the mechanisms: what each of the three receptors involved — GLP-1, GIP, and glucagon — actually does, and why combining them is mechanistically different from simply increasing the dose of a single-target compound.

Three receptors, three native hormones

• GLP-1 receptor. Activated by glucagon-like peptide-1, released from intestinal L-cells after eating. Its downstream effects include glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite signaling.
• GIP receptor. Activated by glucose-dependent insulinotropic polypeptide, released from intestinal K-cells. Historically considered the "other" incretin alongside GLP-1, with effects on insulin secretion and, notably, direct actions on adipose tissue and lipid metabolism that GLP-1 doesn't share.
• Glucagon receptor. Activated by glucagon itself, released from pancreatic alpha cells. Classically associated with raising blood glucose (the opposite direction from insulin) by promoting glycogen breakdown in the liver, but also implicated in increasing energy expenditure — a property that makes it mechanistically interesting when combined with the other two pathways rather than targeted alone.

Tirzepatide: dual GIP/GLP-1 agonism

Tirzepatide was engineered to activate both the GIP and GLP-1 receptors from a single peptide backbone. This was a departure from the assumption, common in earlier incretin research, that GIP receptor agonism wasn't a particularly useful target on its own. Combining it with GLP-1 agonism produced research outcomes that prompted a broader re-evaluation of GIP's role — an example of how a multi-receptor approach can reveal biology that single-target research had underestimated.

Retatrutide: adding the glucagon receptor

Retatrutide extends the same logic one step further, engaging GLP-1, GIP, and glucagon receptors from a single molecule. The inclusion of glucagon receptor agonism is the mechanistically distinct piece: unlike GLP-1 and GIP, which both amplify insulin secretion, glucagon receptor activation is associated in the research literature with increased hepatic glucose output and higher energy expenditure. Balancing that effect against the insulin-amplifying effects of the other two receptors is an active area of pharmacological research, and represents a genuinely different design philosophy than simply adding more GLP-1 agonism.

Why "triple agonist" isn't just "stronger"

A common oversimplification is treating a triple agonist as a more potent version of a single-target compound. Mechanistically, that's not quite right — each receptor contributes a functionally distinct effect, and the research interest in multi-receptor agonists lies specifically in how those distinct effects interact, not merely in a larger cumulative effect on any single pathway. This is also why receptor selectivity ratios (how strongly a compound activates each receptor relative to the others) are a meaningful variable that research teams tune deliberately, rather than an incidental byproduct of the molecule's design.

The interesting research question with multi-receptor agonists isn't "how much stronger is this," but "what does engaging these specific receptors together produce that engaging them separately would not."

Where the comparative research stands

Head-to-head comparisons between dual and triple agonists, and between different receptor-selectivity ratios within each class, remain an active area of ongoing clinical and preclinical investigation. As with the broader incretin literature discussed in our history article, this is a fast-moving field, and receptor pharmacology data should be treated as a snapshot of current understanding rather than a final answer.